

AMENDMENTS TO THE CLAIMS

1. (Original) An epitope for binding integrins, comprising strands A and G of domain 1 of ICAM-4 (SEQ ID NO: 1), in which the A strand (SEQ ID NO: 2) is defined by amino acid residues 17 to 27 of ICAM-4 and the G strand (SEQ ID NO: 3) is defined by amino acid residues 90 to 100 of ICAM-4, or a functional homologue of the epitope.
2. (Original) The epitope according to claim 1, defined by amino acid residues F18, W19, V20 on the A strand of ICAM-4 and amino acid residues R92, A94, T95, S96 and R97 on the G strand of ICAM-4.
3. (Currently amended) The epitope according to ~~either of claim 1 or claim 2~~, modified in that the A strand is replaced by strand F on domain 1 of ICAM-4, in which the F strand (SEQ ID NO: 4) is defined by amino acid residues 77 to 87 of ICAM-4.
4. (Original) The epitope according to claim 3, defined by amino acid residues W77 and L80 on the F strand of ICAM-4 and amino acid residues R92, A94, T95, S96 and R97 on the G strand of ICAM-4.
5. (Currently amended) The epitope according to ~~any preceding~~ claim 1, further defined by amino acid residues W66 on the E strand of domain 1 of ICAM-4 and K118 on the B strand of domain 2 of ICAM-4, in which the E strand (SEQ ID NO: 5) is defined by amino acid residues 160 to 170 of ICAM-4 and the B strand (SEQ ID NO: 6) is defined by amino acid residues 116 to 126 of ICAM-4.

6. (Currently amended) The epitope according to ~~any preceding~~ claim 1, further defined by amino acid residues N160, V161 and T162 on the E strand of ICAM-4.

7. (Currently amended) The epitope according to ~~any preceding~~ claim 1, in which the integrins are α_v integrins (for example, as found on HT1080 cells), $\alpha_4\beta_1$ (also known as VLA-4; for example, as found on HEL cells and erythroblasts), or $\alpha_5\beta_1$ (for example, as found on erythroblasts).

8. (Currently amended) A footprint domain for binding integrins, comprising a first epitope as defined in ~~any of claims 1 to 6~~ claim 1 and a second epitope comprising the C and F strands of domain 1 of ICAM-4 and the CE loop of domain 2 of ICAM-4, in which the C strand (SEQ ID NO: 7) is defined by amino acid residues 47 to 54 of ICAM-4, the F strand (SEQ ID NO: 4) is defined by amino acid residues 77 to 87 of ICAM-4 and the CE loop (SEQ ID NO: 8) is defined by amino acid residues 150 to 158 of ICAM-4, or a functional homologue of the footprint domain.

9. (Original) The footprint domain according to claim 8, in which the second epitope is defined by amino acid residues R52 on the C strand of ICAM-4, W77 and L80 on the F strand of ICAM-4, T91, W93 and R97 on the G strand of ICAM-4, and E151 and T154 on the C'-E loop of ICAM-4.

10. (Currently amended) The footprint domain according to ~~either of claim 8 or claim 9~~, in which the integrin ligands are α_v integrins (for example, as found on HT1080 cells), VLA-4 (for example, as found on HEL cells) and/or the β_2 -family of integrins (such as Mac-1, for example, as found on leucocytes and on neutrophils, and/or LFA-1), including $\alpha L\beta 2$ (for example, as found on neutrophils).

11. (Currently amended) An antagonist of the epitope of claims ~~1 to 7 and/or the footprint domain of claims 8 to 10~~.

12. (Currently amended) An antagonist of a ligand for the epitope of claims ~~1 to 7 and/or the footprint domain of claims 8 to 10~~.

13. (Original) The antagonist of claim 12, having or consisting essentially of three, four, five, six, seven, eight, nine or more amino acid residues of the A, C, F or G strands or the CE loop of ICAM-4, or a functional homologue thereof.

14. (Original) The antagonist of claim ~~14~~ 12, in which the antagonist has or consists essentially of the amino acid sequence according to SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11.

15. (Currently amended) A method of antagonising the epitope of claims ~~1 to 7 and/or the footprint domain of claims 8 to 10~~, comprising the step of contacting the epitope ~~and/or the footprint domain~~ with ~~the~~ an antagonist of ~~claim 11~~ the epitope for binding integrins.

16. (Currently amended) A method of antagonising a ligand of the epitope of claims 1 ~~to 7 and/or the footprint domain of claims 8 to 10~~, comprising the step of contacting the ligand with ~~the~~ an antagonist of ~~any of claims 12 to 14~~ a ligand of the epitope for binding integrins.

17. (Currently amended) ~~Use of~~ A method of treating a disease using the antagonist of ~~any of claims 11 to 14~~ claim 11 for treating a disease.

18. (Currently amended) The ~~use~~ method according to claim 17, in which the disease involves ICAM-4.

19. (Currently amended) ~~Use of the antagonist~~ A method of making a medicament for the treatment of a disease comprising the antagonist according to ~~any of claims 11 to 14 in the manufacture of a medicament for the treatment of a disease involving~~ claim 11, wherein the disease involves ICAM-4.

20. (Currently amended) The ~~use~~ method according to ~~any of claims 17 to 19~~ claim 17, in which disease is characterised by increased levels of ICAM-4 binding.

21. (Currently amended) The ~~use~~ method according to ~~any of claims 17 to 19~~ claim 17, in which the disease is characterised by decreased levels of ICAM-4 binding.

22. (Currently amended) The ~~use~~ method according to ~~any of claims 17 to 21~~ claim 17, in which the disease is sickle cell disease, deep vein thrombosis (DVT), malaria, heart disease, vascular complications, diabetes, β -thalassemia, or a thrombotic complication of haematological diseases.

23. (Currently amended) An isolated nucleotide encoding the epitope defined in claims ~~1 to 7 or the footprint domain of claims 8 to 10~~ or ~~the~~ an antagonist ~~of claims 11 to 14~~ thereof.

24. (Original) The isolated nucleotide of claim 23, having a sequence defined within the sequence of SEQ ID NO: 12.